ArticleBMC oral health2026
Targeted nanocomposite delivery system of amygdalin using chitosan/reduced graphene oxide-zinc oxide/hyaluronic acid for treatment of head and neck squamous cell carcinoma.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) is a major and growing public health problem due to its global high incidence and mortality. Most conventional treatments have adverse side effects due to lack of selectivity and targetabiliy, which has increased the demand for more precise and safe alternatives. Amygdalin (AMG) is a plant-derived cyanoglycoside with a potent anticancer effect, however, its therapeutic use remains controversial due to safety concerns.
objectiveNanotechnology can improve the targeted delivery of AMG while reducing its drawbacks. This study aimed to develop a nanocomposite comprised of chitosan (CS), reduced graphene oxide (rGO), zinc oxide nanoparticles (ZnO NPs), and hyaluronic acid (HA) to serve as a nanocomposite for controlled release and targeted delivery of AMG.
methodsAMG-loaded (CS/rGO-ZnO/HA) nanocomposite was prepared by the ion gelation technique using tripolyphosphate (TPP) as a crosslinker. Blank and AMG-loaded nanocomposites were characterized using FTIR, XRD, TEM, SEM, DSC, and TGA. In vitro drug release was conducted via the dialysis bag method. In vitro anticancer effect of the prepared nanocomposite was evaluated via cell viability, wound scratch, and cellular uptake assays.
resultsAMG-loaded nanocomposite manifested a particle size of 180.2 ± 2.13 nm with a negative surface charge of -36.5 ± 4.96 mV, high encapsulation efficiency (90.81%±1.23), and pH-dependent controlled release. Moreover, AMG-loaded nanocomposite exhibited a much lower IC50 value in comparison to free AMG when examined against A-341 cells. In addition, AMG-loaded nanocomposite demonstrated improved anti-migratory effect, associated with enhanced cellular uptake due to its active targeting potential.
conclusionAMG-loaded nanocomposite could be considered a promising targeted nanoplatform for managing head and neck squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.